Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
- Written by PR Newswire
 |
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose
Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile
SKY-0515's Phase 2/3 FALCON-HD trial in patients in Australia and New Zealand is...
